| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2012PLoSO...735981F |
| P5530 | Altmetric DOI | 10.1371/JOURNAL.PONE.0035981 |
| P6409 | CORE output ID | 90295838 |
| P6179 | Dimensions Publication ID | 1018232320 |
| P356 | DOI | 10.1371/JOURNAL.PONE.0035981 |
| P953 | full work available online at | http://eprints.whiterose.ac.uk/86668/ |
| http://dx.plos.org/10.1371/journal.pone.0035981 | ||
| https://europepmc.org/articles/PMC3362588 | ||
| https://europepmc.org/articles/PMC3362588?pdf=render | ||
| https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0035981&type=printable | ||
| P932 | PMC publication ID | 3362588 |
| P698 | PubMed publication ID | 22666318 |
| P5875 | ResearchGate publication ID | 225187209 |
| P1154 | Scopus EID | 2-s2.0-84861538114 |
| P50 | author | Peter Selby | Q46220287 |
| P2093 | author name string | Paul Evans | |
| Peter J. Selby | |||
| Gordon Cook | |||
| Katherine McKinley | |||
| Sylvia Feyler | |||
| Christopher Parrish | |||
| Mike Short | |||
| Sarah Jarmin | |||
| Gina B. Scott | |||
| P2860 | cites work | IL4 blockade of inducible regulatory T cell differentiation: the role of Th2 cells, Gata3 and PU.1. | Q82791344 |
| Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients | Q42742001 | ||
| Interleukin-12 converts Foxp3+ regulatory T cells to interferon-γ-producing Foxp3+ T cells that inhibit colitis. | Q42747710 | ||
| Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after | Q42803845 | ||
| Establishment and characterization of five human myeloma cell lines | Q42814303 | ||
| Establishment of five human myeloma cell lines | Q42816610 | ||
| Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery | Q43095588 | ||
| Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells | Q45878833 | ||
| IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells | Q46040716 | ||
| Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells | Q46490320 | ||
| In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma | Q51985543 | ||
| TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation. | Q54641474 | ||
| CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden | Q56461588 | ||
| ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement | Q56905227 | ||
| Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse | Q58211903 | ||
| Blocking inducible co-stimulator in the absence of CD28 impairs Th1 and CD25+ regulatory T cells in murine colitis | Q75303091 | ||
| Molecular mechanisms and therapeutic reversal of immune suppression in cancer | Q79787000 | ||
| Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression | Q80752312 | ||
| CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers | Q81317188 | ||
| Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells | Q81510484 | ||
| Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 | Q24672849 | ||
| Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells | Q33873201 | ||
| CD4+CD25+Foxp3+IFN-γ+ human induced T regulatory cells are induced by interferon-γ and suppress alloresponses nonspecifically | Q33929883 | ||
| Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis | Q34048386 | ||
| TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells | Q34565392 | ||
| Rapid suppression of cytokine transcription in human CD4+CD25 T cells by CD4+Foxp3+ regulatory T cells: independence of IL-2 consumption, TGF-beta, and various inhibitors of TCR signaling | Q34582454 | ||
| Regulatory T cells in the induction and maintenance of peripheral transplantation tolerance | Q35069619 | ||
| The molecular mechanisms of Foxp3 gene regulation. | Q35490792 | ||
| Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. | Q35606345 | ||
| Mechanism and therapeutic reversal of immune suppression in cancer | Q35990479 | ||
| Human CD4+ regulatory T cells and activation-induced tolerance. | Q36127323 | ||
| Immunotherapy in multiple myeloma--possibility or probability? | Q36206601 | ||
| Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer | Q36248401 | ||
| Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention | Q36254020 | ||
| CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness | Q36370807 | ||
| Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation | Q36403539 | ||
| CD4 regulatory T cells in human cancer pathogenesis | Q36526954 | ||
| Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms | Q36568027 | ||
| Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity | Q36605447 | ||
| The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer. | Q37068196 | ||
| Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells | Q37085357 | ||
| IL-17-producing human peripheral regulatory T cells retain suppressive function | Q37176541 | ||
| Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. | Q37208910 | ||
| Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. | Q37234611 | ||
| Regulatory T cells and the induction of IL-17. | Q37349778 | ||
| Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function | Q37405703 | ||
| FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival | Q40090775 | ||
| CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients | Q40212457 | ||
| Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. | Q40797196 | ||
| Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes | Q40909490 | ||
| Production of fibronectin and adherence to fibronectin by human myeloma cell lines | Q41465157 | ||
| The yin and yang of signaling in Tregs and TH17 cells | Q41495335 | ||
| Normal and neoplastic human plasma cells express bcl-2 antigen. | Q41666022 | ||
| Adaptive human regulatory T cells: myth or reality? | Q41762576 | ||
| Dysfunctional T regulatory cells in multiple myeloma | Q41877240 | ||
| Runx proteins regulate Foxp3 expression | Q42594337 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple myeloma | Q467635 |
| P304 | page(s) | e35981 | |
| P577 | publication date | 2012-05-29 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent | |
| Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent | |||
| P478 | volume | 7 |
| Q56889868 | APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications |
| Q88109417 | Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression |
| Q33651495 | Checkpoint inhibitors in hematological malignancies |
| Q38155039 | Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma |
| Q42201062 | Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients |
| Q64988615 | Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. |
| Q36447553 | Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities |
| Q41370609 | Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma |
| Q38053765 | Epigenetics, autoimmunity and hematologic malignancies: A comprehensive review |
| Q35551328 | Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells. |
| Q84944212 | Has the T cell bitten off more than it can chew? |
| Q94475277 | Identification of the immune checkpoint signature of multiple myeloma using mass cytometry-based single-cell analysis |
| Q36375348 | Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy |
| Q43213085 | Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients |
| Q55261270 | Increased circulating CD4+FOXP3+ T cells associate with early relapse following autologous hematopoietic stem cell transplantation in multiple myeloma patients. |
| Q92712433 | Mass Cytometry Discovers Two Discrete Subsets of CD39-Treg Which Discriminate MGUS From Multiple Myeloma |
| Q34482050 | Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. |
| Q38097311 | Modulating T regulatory cells in cancer: how close are we? |
| Q39901834 | Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma |
| Q47985426 | Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state |
| Q47326177 | Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma |
| Q38102479 | Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM) |
| Q38815399 | Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma |
| Q38970585 | Targeting the Bone Marrow Microenvironment. |
| Q38289041 | Targeting the bone marrow microenvironment in multiple myeloma. |
| Q35669068 | The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies |
Search more.